Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma

Journal of Immunology

Volumn 189, Issue 5, 2012, Pages 2226-2233

  Forte, Giovanni ^a   Sorrentino, Rosalinda ^a   Montinaro, Antonella ^a   Luciano, Antonio ^b   Adcock, Ian M ^c   Maiolino, Piera ^b   Arra, Claudio ^b   Cicala, Carla ^d   Pinto, Aldo ^a   Morello, Silvana ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ALPHA,BETA METHYLENEADENOSINE DIPHOSPHATE; CD20 ANTIGEN; CD8 ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2B; INTERLEUKIN 17; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE MODEL; ENZYME INHIBITION; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; MELANOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TH1 CELL; TH17 CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR REGRESSION;

5'-NUCLEOTIDASE; ADENOSINE DIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CELL LINE, TUMOR; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, NUDE; TH1 CELLS; TH17 CELLS;

EID: 84865429151     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200744     Document Type: Article

References (49)

1. Drake, C. G., E. Jaffee, and D. M. Pardoll. 2006. Mechanisms of immune evasion by tumors. Adv. Immunol. 90: 51-81.
2. Ohta, A., E. Gorelik, S. J. Prasad, F. Ronchese, D. Lukashev, M. K. Wong, X. Huang, S. Caldwell, K. Liu, P. Smith, et al. 2006. A2A adenosine receptor protects tumors from antitumor T cells. Proc. Natl. Acad. Sci. USA 103: 13132-13137.
3. Stagg, J., and M. J. Smyth. 2010. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 29: 5346-5358.
4. Blay, J., T. D. White, and D. W. Hoskin. 1997. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res. 57: 2602-2605.
5. Pellegatti, P., L. Raffaghello, G. Bianchi, F. Piccardi, V. Pistoia, and F. Di Virgilio. 2008. Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS ONE 3: e2599.
6. Zhang, H., D. M. Conrad, J. J. Butler, C. Zhao, J. Blay, and D. W. Hoskin. 2004. Adenosine acts through A2 receptors to inhibit IL-2-induced tyrosine phosphorylation of STAT5 in T lymphocytes: role of cyclic adenosine 39,5′-monophosphate and phosphatases. J. Immunol. 173: 932-944.
7. Huang, S., S. Apasov, M. Koshiba, and M. Sitkovsky. 1997. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood 90: 1600-1610.
8. Ohta, A., A. Ohta, M. Madasu, R. Kini, M. Subramanian, N. Goel, and M. Sitkovsky. 2009. A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments. J. Immunol. 183: 5487-5493.
9. Spychala, J. 2000. Tumor-promoting functions of adenosine. Pharmacol. Ther. 87: 161-173.
10. Resta, R., Y. Yamashita, and L. F. Thompson. 1998. Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol. Rev. 161: 95-109.
11. Colgan, S. P., H. K. Eltzschig, T. Eckle, and L. F. Thompson. 2006. Physiological roles for ecto-59-nucleotidase (CD73). Purinergic Signal. 2: 351-360.
12. Yamashita, Y., S. W. Hooker, H. Jiang, A. B. Laurent, R. Resta, K. Khare, A. Coe, P. W. Kincade, and L. F. Thompson. 1998. CD73 expression and fyn-dependent signaling on murine lymphocytes. Eur. J. Immunol. 28: 2981-2990.
13. Deaglio, S., K. M. Dwyer, W. Gao, D. Friedman, A. Usheva, A. Erat, J. F. Chen, K. Enjyoji, J. Linden, M. Oukka, et al. 2007. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204: 1257-1265.
14. Zhang, B. 2010. CD73: a novel target for cancer immunotherapy. Cancer Res. 70: 6407-6411.
15. Stagg, J., U. Divisekera, N. McLaughlin, J. Sharkey, S. Pommey, D. Denoyer, K. M. Dwyer, and M. J. Smyth. 2010. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc. Natl. Acad. Sci. USA 107: 1547-1552.
16. Jin, D., J. Fan, L. Wang, L. F. Thompson, A. Liu, B. J. Daniel, T. Shin, T. J. Curiel, and B. Zhang. 2010. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res. 70: 2245-2255.
17. Stagg, J., U. Divisekera, H. Duret, T. Sparwasser, M. W. Teng, P. K. Darcy, and M. J. Smyth. 2011. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res. 71: 2892-2900.
18. Wang, L., J. Fan, L. F. Thompson, Y. Zhang, T. Shin, T. J. Curiel, and B. Zhang. 2011. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J. Clin. Invest. 121: 2371-2382.
19. DiLillo, D. J., K. Yanaba, and T. F. Tedder. 2010. B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J. Immunol. 184: 4006-4016.
20. Sorrentino, R., S. Morello, G. Forte, A. Montinaro, G. De Vita, A. Luciano, G. Palma, C. Arra, P. Maiolino, I. M. Adcock, and A. Pinto. 2011. B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma. Am. J. Respir. Crit. Care Med. 183: 1369-1379.
21. Yegutkin, G. G., F. Marttila-Ichihara, M. Karikoski, J. Niemelä, J. P. Laurila, K. Elima, S. Jalkanen, and M. Salmi. 2011. Altered purinergic signaling in CD73-deficient mice inhibits tumor progression. Eur. J. Immunol. 41: 1231-1241.
22. Gimotty, P. A., P. Van Belle, D. E. Elder, T. Murry, K. T. Montone, X. Xu, S. Hotz, S. Raines, M. E. Ming, P. Wahl, and D. Guerry. 2005. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J. Clin. Oncol. 23: 8048-8056.
23. Sorrentino, R., S. Morello, A. Luciano, T. R. Crother, P. Maiolino, E. Bonavita, C. Arra, I. M. Adcock, M. Arditi, and A. Pinto. 2010. Plasmacytoid dendritic cells alter the antitumor activity of CpG-oligodeoxynucleotides in a mouse model of lung carcinoma. J. Immunol. 185: 4641-4650.
24. Deaglio, S., and S. C. Robson. 2011. Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity. Adv. Pharmacol. 61: 301-332.
25. van de Veerdonk, F. L., B. Lauwerys, R. J. Marijnissen, K. Timmermans, F. Di Padova, M. I. Koenders, I. Gutierrez-Roelens, P. Durez, M. G. Netea, J. W. van der Meer, et al. 2011. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum. 63: 1507-1516.
26. Zhang, M., Z. Wang, M. W. Graner, L. Yang, M. Liao, Q. Yang, J. Gou, Y. Zhu, C. Wu, H. Liu, et al. 2011. B cell infiltration is associated with the increased IL-17 and IL-22 expression in the lungs of patients with tuberculosis. Cell. Immunol. 270: 217-223.
27. Kryczek, I., M. Banerjee, P. Cheng, L. Vatan, W. Szeliga, S. Wei, E. Huang, E. Finlayson, D. Simeone, T. H. Welling, et al. 2009. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114: 1141-1149.
28. Qin, Z., G. Richter, T. Schüler, S. Ibe, X. Cao, and T. Blankenstein. 1998. B cells inhibit induction of T cell-dependent tumor immunity. Nat. Med. 4: 627-630.
29. Shah, S., A. A. Divekar, S. P. Hilchey, H. M. Cho, C. L. Newman, S. U. Shin, H. Nechustan, P. M. Challita-Eid, B. M. Segal, K. H. Yi, and J. D. Rosenblatt. 2005. Increased rejection of primary tumors in mice lacking B cells: inhibition of antitumor CTL and TH1 cytokine responses by B cells. Int. J. Cancer 117: 574-586.
30. Brodt, P., and J. Gordon. 1978. Anti-tumor immunity in B lymphocyte-deprived mice. I. Immunity to a chemically induced tumor. J. Immunol. 121: 359-362.
31. Barbera-Guillem, E., M. B. Nelson, B. Barr, J. K. Nyhus, K. F. May, Jr., L. Feng, and J. W. Sampsel. 2000. B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion. Cancer Immunol. Immunother. 48: 541-549.
32. Kim, S., Z. G. Fridlender, R. Dunn, M. R. Kehry, V. Kapoor, A. Blouin, L. R. Kaiser, and S. M. Albelda. 2008. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models. J. Immunother. 31: 446-457.
33. Watt, V., F. Ronchese, and D. Ritchie. 2007. Resting B cells suppress tumor immunity via an MHC class-II dependent mechanism. J. Immunother. 30: 323-332.
34. Inoue, S., W. W. Leitner, B. Golding, and D. Scott. 2006. Inhibitory effects of B cells on antitumor immunity. Cancer Res. 66: 7741-7747.
35. Li, Q., S. Teitz-Tennenbaum, E. J. Donald, M. Li, and A. E. Chang. 2009. In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy. J. Immunol. 183: 3195-3203.
36. Anderson, S. M., M. M. Tomayko, A. Ahuja, A. M. Haberman, and M. J. Shlomchik. 2007. New markers for murine memory B cells that define mutated and unmutated subsets. J. Exp. Med. 204: 2103-2114.
37. Minguet, S., M. Huber, L. Rosenkranz, W. W. Schamel, M. Reth, and T. Brummer. 2005. Adenosine and cAMP are potent inhibitors of the NF-kappa B pathway downstream of immunoreceptors. Eur. J. Immunol. 35: 31-41.
38. Iwakura, Y., H. Ishigame, S. Saijo, and S. Nakae. 2011. Functional specialization of interleukin-17 family members. Immunity 34: 149-162.
39. Numasaki, M., J. Fukushi, M. Ono, S. K. Narula, P. J. Zavodny, T. Kudo, P. D. Robbins, H. Tahara, and M. T. Lotze. 2003. Interleukin-17 promotes angiogenesis and tumor growth. Blood 101: 2620-2627.
40. Wang, L., T. Yi, M. Kortylewski, D. M. Pardoll, D. Zeng, and H. Yu. 2009. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 206: 1457-1464.
41. Benchetrit, F., A. Ciree, V. Vives, G. Warnier, A. Gey, C. Sautès-Fridman, F. Fossiez, N. Haicheur, W. H. Fridman, and E. Tartour. 2002. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 99: 2114-2121.
42. Hirahara, N., Y. Nio, S. Sasaki, Y. Minari, M. Takamura, C. Iguchi, M. Dong, K. Yamasawa, and K. Tamura. 2001. Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice. Oncology 61: 79-89.
43. Martin-Orozco, N., P. Muranski, Y. Chung, X. O. Yang, T. Yamazaki, S. Lu, P. Hwu, N. P. Restifo, W. W. Overwijk, and C. Dong. 2009. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31: 787-798.
44. Kryczek, I., S. Wei, W. Szeliga, L. Vatan, and W. Zou. 2009. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 114: 357-359.
45. Hinrichs, C. S., A. Kaiser, C. M. Paulos, L. Cassard, L. Sanchez-Perez, B. Heemskerk, C. Wrzesinski, Z. A. Borman, P. Muranski, and N. P. Restifo. 2009. Type 17 CD8+ T cells display enhanced antitumor immunity. Blood 114: 596-599.
46. Fletcher, J. M., R. Lonergan, L. Costelloe, K. Kinsella, B. Moran, C. O'Farrelly, N. Tubridy, and K. H. Mills. 2009. CD39+Foxp3+ regulatory T cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J. Immunol. 183: 7602-7610.
47. Mitsdoerffer, M., Y. Lee, A. Jäger, H. J. Kim, T. Korn, J. K. Kolls, H. Cantor, E. Bettelli, and V. K. Kuchroo. 2010. Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc. Natl. Acad. Sci. USA 107: 14292-14297.
48. Wu, H. J., I. I. Ivanov, J. Darce, K. Hattori, T. Shima, Y. Umesaki, D. R. Littman, C. Benoist, and D. Mathis. 2010. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 32: 815-827.
49. Doreau, A., A. Belot, J. Bastid, B. Riche, M. C. Trescol-Biemont, B. Ranchin, N. Fabien, P. Cochat, C. Pouteil-Noble, P. Trolliet, et al. 2009. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat. Immunol. 10: 778-785.